BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

April 7, 2017

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and microbe interactions. Seventure has just published a report on the emergence of the microbiome as an intense area of interest in the biotech industry, starting with the advent of deep sequencing technology in the early 2000s and moving toward the Phase II trials in progress now.

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its...

Next Video
BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech
BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech

Antoine Papiernik is the chairman of Paris-based Sofinnova Partners, a venture capital firm that invests in...